Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02416271 · ClinicalTrials.gov registry record · Phase 4
The Forteo Alendronate Comparator Trial
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 203
- Enrollment target
NCT02416271 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 203 participants.
The verdict
NCT02416271, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 203 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (BMD) and other osteoporosis factors in postmenopausal women with osteoporosis.
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- DRUG Teriparatide
- DRUG Alendronate
- DIETARY_SUPPLEMENT Calcium
- DRUG Placebo-Oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2001-04 |
| Est. Completion | 2003-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02416271
The ClinicalTrials.gov registry entry for NCT02416271 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vitamin D is the first listed.
NCT02416271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02416271 about?
NCT02416271 is a clinical study titled "The Forteo Alendronate Comparator Trial". The main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (BMD) and other osteoporosis factors in postmenopausal women with osteoporosis.
What is the current status of trial NCT02416271?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 203 participants. The study started on 2001-04. Estimated completion is 2003-05.
What interventions are being tested in trial NCT02416271?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), Teriparatide (DRUG), Alendronate (DRUG), Calcium (DIETARY_SUPPLEMENT), Placebo-Oral (DRUG).
Who is sponsoring clinical trial NCT02416271?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.